Foreman Emma, Patel Himanshu, Siderov Jim, Harchowal Jatinder, Bubalo Joseph, Chan Alexandre
Royal Marsden NHS Foundation Trust, London, UK.
International Society of Oncology Pharmacy Practicioners, Vancouver, Canada.
J Oncol Pharm Pract. 2020 Apr;26(3_suppl):22-32. doi: 10.1177/1078155220913098.
The International Society of Oncology Pharmacy Practitioners (ISOPP) Biosimilars Task Force was charged to develop educational activities and resources to assist members when implementing biosimilar medicines into their local practice. To facilitate the process, the task force conducted a survey in order to understand biosimilar implementation practice by ISOPP members across the world and the challenges that oncology pharmacists face when adopting biosimilars into their clinical practice.
A cross-sectional survey was conducted between 20 April 2019 and 27 May 2019. Members of ISOPP and a number of national oncology pharmacy groups were invited to complete the survey. The survey contained 29 items and consisted of three sections: respondents’ demographics, respondents’ institutional practice relating to biosimilar implementation and post implementation practice at the respondents’ institutions. Descriptive statistics were utilized to analyze the survey results.
A total of 265 ISOPP members were surveyed, with 50 members providing a response (response rate = 19%). In addition, 40 nonmembers participated in the survey, bringing the total to 90 respondents. The most common factors that influence the decision to implement use of a biosimilar as reported by respondents are medication costs/pricing (92%), available clinical data (73%), and product availability (63%). Respondents also commented on the barriers to biosimilar implementation at their institutions, which included a reluctance of prescribers to use biosimilars (due to the lack of familiarity or perceived inferiority), a reluctance to switch established patients from an originator to a biosimilar and the preferences of insurance companies or funding bodies.
The results of this survey reinforce the need for greater education and training for health care professionals in the use of biosimilars, the importance of sharing good practice, and a need for standardization.
国际肿瘤药学从业者协会（ISOPP）生物类似药特别工作组负责开展教育活动并提供相关资源，以帮助成员在当地实践中应用生物类似药。为推动这一进程，特别工作组开展了一项调查，旨在了解全球ISOPP成员的生物类似药应用实践情况，以及肿瘤药师在将生物类似药纳入临床实践时所面临的挑战。
于2019年4月20日至2019年5月27日进行了一项横断面调查。邀请ISOPP成员以及一些国家肿瘤药学团体完成该调查。该调查包含29个项目，分为三个部分：受访者的人口统计学信息、受访者所在机构与生物类似药应用相关的实践情况以及生物类似药在受访者所在机构应用后的实践情况。采用描述性统计分析调查结果。
共对265名ISOPP成员进行了调查，其中50名成员做出了回应（回应率=19%）。此外，40名非成员参与了调查，使总受访者达到90人。受访者报告的影响决定应用生物类似药的最常见因素包括药品成本/定价（92%）、可用临床数据（73%）和产品可及性（63%）。受访者还对其所在机构生物类似药应用的障碍发表了评论，包括处方医生不愿使用生物类似药（由于缺乏熟悉度或认为其质量较差）、不愿将现有患者从原研药转换为生物类似药以及保险公司或资助机构的偏好。
本次调查结果强化了对医疗保健专业人员进行生物类似药使用方面更多教育和培训的必要性、分享良好实践的重要性以及标准化的需求。
